Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTELO BIOSCIENCES, INC.ARTL · Entity 8413 | Director | July 17, 2026 | July 21, 2026 |
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director · President and CEO | January 28, 2025 | January 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTELO BIOSCIENCES, INC.
Report date July 17, 2026 · Filed July 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-07-17 | Direct | 136 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Grant · Acquired 136 · Balance 136 F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
Carisma Therapeutics Inc.
Report date January 28, 2025 · Filed January 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-01-28 | Direct | 500,000 |
Reported balance
After 2025-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-28 · Grant · Acquired 500,000 · Balance 500,000 F1: The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2026 Filed Jul 21, 2026 22:25 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 136 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001640334-26-001223 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires 2036-07-17 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:48 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Options (right to buy) · Derivative | 292 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001640334-26-000196 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292 Underlying: Common Stock · 292 shares Expires 2036-01-30 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 16:01 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001104659-25-007565 · tm254883-1_4seq1.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:01 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001640334-24-001927 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2034-12-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean December 20, 2024. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 19:05 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-24-072975 · tm2417501-1_4seq1.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 12 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 11 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2033-06-30 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 10 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2032-06-24 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 9 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2031-07-16 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 9,634 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 8 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,634 Underlying: Common Stock · 9,634 shares Expires 2031-02-12 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,484 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 7 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,484 Underlying: Common Stock · 1,484 shares Expires 2029-08-29 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $2.01 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 6 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F7 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.99 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 5 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2033-06-30 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F6 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 4 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2032-06-24 F5 · derivative.exercise_price: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F5 · derivative.underlying_shares: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 3 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2031-07-16 F4 · derivative.exercise_price: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F4 · derivative.underlying_shares: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 9,634 | Not disclosed Strike: $39.90 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 2 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,634 shares Expires 2031-02-12 F3 · derivative.exercise_price: This option was granted on February 12, 2021 and was previously reported as covering 144,500 shares at an exercise price of $2.66 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F3 · derivative.underlying_shares: This option was granted on February 12, 2021 and was previously reported as covering 144,500 shares at an exercise price of $2.66 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 1,484 | Not disclosed Strike: $29.85 | Not disclosed |
DisclosureSEC source: 0001640334-24-000333 · primary_doc.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,484 shares Expires 2029-08-29 F1 · derivative.exercise_price: This option was granted on August 29, 2019 and was previously reported as covering 22,250 shares at an exercise price of $1.99 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F1 · derivative.underlying_shares: This option was granted on August 29, 2019 and was previously reported as covering 22,250 shares at an exercise price of $1.99 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:52 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 438,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-24-010106 · tm245034-1_4seq1.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,000 Underlying: Common Stock · 438,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:55 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,083 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001640334-23-001484 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F1 · derivative.exercise_date: (1) Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 18:07 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001640334-23-001205 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2033-06-30 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:20 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001104659-23-069503 · tm2318219-7_4seq.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vesting on June 6, 2024 and the remaining shares vesting over the next three years thereafter in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:32 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 415,968 | Not disclosed Strike: $1.46 | Not disclosed |
DisclosureSEC source: 0001104659-23-030753 · tm238905-10_4seq1.xml · derivative · entry 2 Kelly Steven · CIK 0001339478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,968 Underlying: Common Stock · 415,968 shares Expires 2031-03-31 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." F4 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vested on April 1, 2022 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:32 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 625,797 | Not disclosed Strike: $0.63 | Not disclosed |
DisclosureSEC source: 0001104659-23-030753 · tm238905-10_4seq1.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,797 Underlying: Common Stock · 625,797 shares Expires 2028-09-18 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 21:18 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001640334-22-001359 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-24 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 24, 2022. Read SEC document |
| July 16, 2021 Filed Jul 26, 2021 20:23 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001640334-21-001677 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 16, 2021. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:59 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 144,500 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001640334-21-000373 · form4.xml · derivative · entry 1 Kelly Steven · CIK 0001339478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,500 Underlying: Common Stock · 144,500 shares Expires 2031-02-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, fifty percent (50%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and fifty percent (50%) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the two (2) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 12, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.